While AML-CEBPA generally harbors a favorable prognosis, further studies are required to address best strategies for the treatment of MRD-positive disease, and how to improve the outcomes of co-mutated GATA2, WT1, and CSF3R AML. This evidence concerns the gene CSF3R and acute myeloid leukemia.